Mitotech S.A, based in Luxembourg, is developing SkQ1, a powerful antioxidant that directly targets mitochondria. As a cardiolipin peroxidation inhibitor, SkQ1 protects mitochondria from the effects of oxidative stress. This approach is meant to slow or halt mitochondrial dysfunction, providing a possible therapy for macular degeneration and other age-related diseases.
The company recently completed a phase 2b/3 study, VISTA-2, for SkQ1 as a treatment for dry eye disease which, according to a press release, improved best corrected visual acuity along with other secondary endpoints. Mitotech is planning their next pivotal study for the purpose of NDA submission. Phase 2 studies are projected to start in 2021 for dry AMD and Leber’s Hereditary Optic Neuropathy.